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Abstract
Background—Patient long-term adherence to β-blockers, HMG-CoA reductase inhibitors 
(statins), and angiotensin-converting-enzyme inhibitors (ACEIs)/angiotensin receptor blockers 
(ARBs) after acute myocardial infarction (AMI) is alarmingly low. It is unclear how prevalent 
patient adherence may be across small geographic areas and whether this geographic prevalence 
may vary.
Methods—This is a retrospective cohort study using Medicare service claims files from 2007 to 
2009 with Medicare beneficiaries ≥ 65 years who were alive 30 days after the index AMI 
hospitalization between 1/1/2008 to 12/31/2008 (N=85,017). The adjusted proportions of patients 
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adherent to β-blockers, statins, and ACEIs/ARBs respectively in the 12 months after discharge 
across the 306 Hospital Referral Regions (HRRs) were measured and compared by control chart. 
The intracluster correlation coefficient (ICC) and the additional prediction power from this small-
area variation on individual patient adherence were assessed.
Results—The adjusted proportion of patients adherent across HRRs ranged from 58% to 74% 
(median, 66%) for β-blockers, from 57% to 67% (median, 63%) for ACEIs/ARBs, and from 58% 
to 73% (median, 66%) for statins. The ICC was 0.053 (95% CI, 0.043–0.064) for β-blockers, 
0.050 (95% CI, 0.039–0.061) for ACEIs/ARBs, and 0.041 (95% CI, 0.031–0.052) for statins. The 
adjusted proportion of patients adherent across HRRs increased the c-statistic by 0.01 to 0.02 
(P<0.0001).
Conclusions—Non-adherence to evidence-based preventive therapies post AMI among older 
adults was prevalent across small geographic regions. Moderate small-area variation in patient 
adherence exists.
Keywords
compliance/adherence; small area variation; acute myocardial infarction; Secondary prevention; 
Medication Adherence; Regional Variation
INTRODUCTION
Clinical guidelines recommend long-term use of β-blockers, HMG-CoA reductase inhibitors 
(statins), angiotensin-converting-enzyme (ACEIs) /angiotensin receptor blockers (ARBs) as 
secondary preventive therapies after acute myocardial infarction (AMI).1,2 Recent studies 
have shown considerable improvements in the prescribing of the preventive therapies at 
discharge after years of implementation of the Get With The Guidelines (GWTG) 
program.3–5 However, evidence-based therapies may not be able to optimally reduce 
mortality and morbidity following AMI if patients do not take them as directed. The benefit 
of these preventive therapies depends on long-term adherence.6–8 Adherence to the 
evidence-based therapies are typically defined as more than 80% of time a patient is covered 
with prescription supply.7 In a recent population-based longitudinal study of 31,455 elderly 
AMI survivors, patients who had low adherence to the evidenced-based therapies had a 25% 
higher mortality risk (95% CI, 9% to 42%) as compared to patients who had high 
adherence.7 It was also shown that non-adherent patients had a 44% higher likelihood (95% 
CI, 15% to 79%) of 1-year mortality than adherent patients after AMI hospital discharge.8 
Another study also showed that AMI patients who were adherent had a 53% lower risk for 
mortality (95% CI, 1% to 79%) and 81% lower risk for recurrent AMI (95% CI, 53% to 
92%).6 However, patient medication adherence following AMI has been shown to be 
worryingly low in general. One year after hospital discharge, approximately half of 
Medicare patients have been shown to be non-adherent to statins, β-blockers, and 
ACEI/ARB treatments.9–11 It has also been argued that medication adherence should be a 
priority for health care reform.12
From a public health perspective, an efficient national intervention program may be 
enhanced by targeting high risk populations, and also areas with a high prevalence of non-
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adherence. Previous studies have shown that there were considerable regional variations in 
prescribing β-blockers, statins, and ACEIs/ARBs at discharge after AMI, which indicated 
difference in the quality of care across regions.13–18 However, it is unclear whether small-
area variation exists in patient longer-term adherence to the prescribed preventive therapies 
following AMI discharge, and the extent of this variation. If such variation in patient 
adherence to the evidence-based preventive therapies exists, identifying these regions with 
high prevalence of patient non-adherence may facilitate future research to design more 
efficient and targeted public health programs and policies to address patient non-adherence 
to evidence-based preventive therapies.
Therefore, this study aimed to 1) assess patient adherence to the 3 evidence-based therapies 
post AMI among a national cohort of older adults who survived AMI in the 12 months after 
their discharge across Dartmouth Atlas Hospital Referral Regions (HRRs) after adjustment 
of non-modifiable patient characteristics; 2) to compare and identify the HRRs with high 
prevalence of non-adherence; and 3) to assess the extent of the variation in patient adherence 
across HRRs and whether the variation added explanation or prediction power of individual 
patient adherence status in addition to individual patient risk factors.
METHODS
Setting and Population
The cohort for this study included all Medicare beneficiaries who were 1) ≥ 65 years old; 2) 
continuously enrolled in the Medicare fee-for-service and prescription Part D programs at 
least 12 months before and until the end of the study period (or death) after an index AMI 
hospitalization; 3) hospitalized for the index AMI between January 1, 2008 to December 31, 
2008 and survived at least 30 days after discharge; 4) were discharged to home or to skilled-
nursing and long-term care facilities and had any prescription claims within 30 days after 
discharge. Hospitalization with AMI was defined as having an international classification of 
diseases (ICD) 9 code of 410.×1 as the primary or secondary discharge diagnosis in 
Medicare inpatient claims.19–21 The first AMI hospitalization in the study period was 
defined as the index AMI hospitalization for each subject.
Primary data used for this study were Medicare service claims and files from the Center for 
the Medicare and Medicaid Services Medicare Chronic Condition Data Warehouse (CCW) 
from 2007 to 2009.22 The CCW files includes inpatient, outpatient, skilled nursing facility, 
carrier (physician office visits), and prescription Part D event service claims files. All CCW 
files are linked by an encrypted and unique CCW identifier number for each beneficiary. 
Other data included the HRRs boundary files, which were linked to CCW files by ZIP codes 
of patient residence.
Treatment Measurement
The use of β-blockers, ACEIs/ARBs, or statins after AMI was defined as 1) filled a 
prescription within the drug class within 30 days after hospital discharge or 2) had a 
prescription supply greater than 30 days from the last prescription filled prior to the AMI 
admission and filled a prescription for the same class of the drug with 60 days after 
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discharge. The specific drug was identified through national drug codes in the Medicare Part 
D prescription event files in the Medicare CCW.
Adherence Measurement
Adherence was measured as the proportion of days covered (PDC) by the prescription 
supply calculated from the prescription refill records in the prescription Part D event files in 
the 12 months (or until death if death occurred within 12 months) post AMI discharge 
among patients who had the preventive therapies within 30 days after AMI discharge.23 The 
adherence measure was also adjusted for over-stock of prescription supply from refills and 
hospital stays during the study period after AMI discharge. Conforming to current literature, 
a patient is defined as adherent if he/she had ≥ 80% of days covered with prescription supply 
in the study period.7
Measurement of Baseline Characteristics/Covariates
Age, gender, and race were determined by using CCW enrollment summary files from the 
index year. Median income for 65 years and older was measured at Census Block Groups 
residence level using 2010 US Census data. Comorbidities were measured by the Charlson 
comorbidity index in the 12 months prior to the index AMI admission using CCW claims 
files.24 Other variables included whether a subject was in the Medicare Part D benefit gap 
(“doughnut-hole”) prior to the index AMI admission, diagnosis of cardiovascular disease 
and other related risk factors in the 12-month baseline [including AMI, coronary artery 
bypass surgery (CABG), stent/percutaneous transluminal coronary angioplasty (PTCA), 
stroke/transient ischemic attack, unstable angina, ischemic heart disease, heart failure, atrial 
fibrillation, peripheral vascular disease, hypertension, diabetes, and hyperlipidemia], 
baseline potential contraindication or intolerant conditions (chronic kidney disease, chronic 
obstructive pulmonary disease, asthma, liver disease, angioedema, hyperkalemia, 
hypotension, sinus bradycardia, heart block, and rhabdomyoloysis/other myopathy), 
prescriptions of β-blockers, ACEIs/ARBs, or statins in the 6 months prior to the index AMI, 
AMI type (subendocardial or transmural infarction), procedures (CABG, stent/PTCA, 
cardiac catheterization, infusion of thrombolytic, infusion of platelet inhibitors) or 
complications (congestive heart failure, cardiogenic shock, acute renal failure, hypotension, 
cardiac dysrhythmias) during the index AMI hospitalization, and total Intensive Care Unit 
(ICU) and inpatient length of stay for the index AMI. Other factor measured include 
discharge destination (home or skilled nursing facilities) and risk factors that may be 
associated with nonadherence such as the total number of different prescription medications 
used (polypharmacy) and diagnosis of dementia in the 12-month baseline were also 
measured. Those characteristics were measured using files based on the standardized 
algorithms in the CCW and other algorithms applied in the literature.22,24,25
Measurement of Small-area Variation in Adherence
To assess small-area variation in patient adherence to the 3 evidence-based therapies post 
AMI, we measured the adjusted proportion of patients who were adherent to each of the 
therapies across Dartmouth HRRs. The Dartmouth HRRs represent regional health care 
markets for tertiary medical care that generally require the services of a major referral 
center.15 The regions were defined by determining where patients were referred for major 
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cardiovascular surgical procedures and for neurosurgery. Each HRR has at least one city 
where both major cardiovascular surgical procedures and neurosurgery are performed. We 
assigned each patient to one of the HRRs on the basis of his/her ZIP code of residence. The 
adjusted proportion of patients adherent to a therapy across HRRs was calculated as the 
predicted number of patients adherent to a therapy divided by the total number of the 
patients in a HRR. The predicted number of patients adherent to a therapy was computed by 
summing all patients’ probabilities of being adherent in each HRR. The probability of being 
adherent for each individual patient was estimated using a mixed-effect hierarchical logistic 
regression model with HRRs as random effects and random intercept (SAS glimmix 
procedure).26–28 The model was adjusted for all measured baseline patient characteristics 
and also the clustering of patients and small and unequal sample sizes across HRRs.26–28 
Sensitivity analysis was also performed for testing and adjusting for spatial autocorrelation.
Analysis
The characteristics of patients who initiated each therapy and the proportion of patients who 
were adherent to each therapy were described. The distribution of mean proportion of days 
covered by a therapy post AMI discharge to a therapy across HRRs was assessed using a 
box plot. The HRRs were ranked by the adjusted proportion of patients adherent to each of 
the 3 therapies. To compare adherence rate across HRRs and identify HRRs with higher 
prevalence of non-adherence, we used control chart to plot the adjusted proportion of 
patients adherent to a therapy across HRRs to identify the HRRs with the proportion below 
the 5th percentile.29
To assess the extent of the variation in patient adherence across HRR, we calculated the 
intraclass (intracluster) correlation coefficient (ICC).30 The ICC is a ratio between the 
between-cluster variance and the total variance of between- and within-cluster variance. The 
mean and the 95% confidence intervals of the ICC were generated by the bootstrap (re-
sampling) of 1000 iterations with replacement from all patients in the cohort.31
To assess whether small-area variation in adherence adds prediction of individual patient 
adherence beyond individual patient risk factors, we compared the c-statistics (Area Under 
the Curve, AUC) from logistic regression models with measured patient characteristics and 
with both patient characteristics and the adjusted proportion of adherent patients across 
HRRs.
All analyses were conducted using SAS version 9.3 (SAS Institute Inc., Cary, NC), and the 
maps were created using ArcGIS version 10 (ESRI Inc., Redlands, CA).
RESULTS
A total of 85,017 patients were included in the final analysis with 64,939 (76%) using β-
blockers, 52,185 (61%) using statins, and 47,127 (55%) using ACEIs/ARBs within 30 days 
after discharge. About 66% users of β-blockers, 66% users of statins and 63% users of 
ACEIs/ARBs were adherent during the 12 months following discharge. Table 1 presents the 
characteristics of patients who initiated the various preventive therapies and the proportion 
of patients adherent for those respective characteristics. For example, approximately 58%, 
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59% and 56% of patients who initiated β-blockers, ACEIs/ARBs were female, respectively. 
The proportion of patients adherent to β-blockers increased from 65% in those 65–74 years 
old to 68% in those 85 years and older, from 62% to 64% for ACEIs/ARBs and from 65% to 
68% for statins. The proportion of patients adherent to β-blockers decreased from 67% 
among patients with a Charlson comorbidity index of 0 to 65% among patients with a 
Charlson comorbidity index of 9 or higher. Patients who had potential contraindicative or 
intolerant conditions to the preventive therapies had lower adherence rates.
The distribution of mean adherence (PDC) across HRR is presented in Appendix 1. The 
mean (standard deviation) is 0.77 (0.031), 0.80 (0.034), 0.079 (0.033) for ACEIs/ARBs, β-
blockers, and statins respectively.
Figure 1 shows the mapping of the proportion of patients adherent to the 3 preventive 
therapies in the 12 months after discharge across HRRs after adjustment for non-modifiable 
factors (patient baseline sociodemographic and clinical characteristics). The proportion of 
patients adherent to β-blockers ranged from 58% to 74% across HRRs, from 58% to 67% for 
ACEIs and ARBs, and from 58% to 73% for statins. The patterns of the regional variation in 
adherence were similar for the 3 therapies. In general, HRRs in the south tend to have lower 
proportion of patients adherent to the 3 therapies than the HRRs in the north.
Figure 2 A–C present the control chart plots of each HRR’s adjusted proportion of patients 
adherent to the 3 preventive therapies, respectively. Each circle in the plots represents a 
HRR. The 3 dashed reference lines represent the 95th percentile, median and 5th percentile 
of the adjusted proportion of patients adherent for a preventive therapy. The median of the 
adjusted proportion of patients adherent to β-blockers across HRRs was 66%, which means 
that half of the HRRs had fewer than 66% of patients adherent to β-blockers. The median of 
the adjusted proportion of patients adherent to statins and ACEIs/ARBs were 66% and 63%, 
respectively. Consistent results were found in sensitivity analysis of adjusting for spatial 
autocorrelation in the mixed-effect hierarchical logistic regression model.
The 5 percentile of adjusted proportion of patients adherent across HRRs was 61%, 60%, 
and 62% for beta-blockers, ACEI/ARBs and statins respectively. Appendix 2 listed the 
HRRs below the 5th percentile of the adjusted proportion of patients adherent for each 
evidence-based preventive therapy. HRR with lowest patient adherence to β-blockers was 
Orlando FL, Jacksonville FL for ACEIs/ARBs, and El Paso TX for Statins.
Table 2 presents the intracluster (intraclass) correlation coefficients to assess the extent of 
the variation in patient adherence to the 3 preventive therapies across HRRs. The ICC 
ranged from 0.041 for statins, to 0.050 for ACEIs/ARBs and to 0.053 for beta-blockers.
Table 3 presents the difference in the AUC between the logistic model with patient 
characteristics and the logistic model with both patient characteristics and the adjusted 
proportion of patients adherent across HRRs. Adding the variation in the proportion of 
patients adherent across HRRs increased the AUC by 0.014 for β-blockers, 0.009 for ACEIs/
ARBs, and 0.012 for statins (p < 0.0001).
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In our study of 85,017 elderly AMI survivors in 2008, we found that non-adherence was 
highly prevalent across the HRRs in the US. Half of the 306 HRRs had fewer than 
approximately 65% of patients adherent to the 3 evidence-based preventive therapies in the 
12 months post AMI. The range in the adjusted proportion of patients adherent to the 3 
evidence-based AMI therapies across HRRs were about 8 to 16 percentage points. The ICC, 
which measures the extent of the adherence variation across HRRs as compared variation 
across individuals, was 0.041 to 0.053. In a review of 31 cluster-based studies on health 
outcomes and clinical practice, it was shown that the median ICC was 0.005 with the 
interquartile ranging from 0 to 0.021 after adjusting for individual and cluster-level 
characteristics.32 Another study of 188 ICCs for primary care health services and binary 
health outcomes found that the median ICC was 0.051 with interquartile from 0.011 to 
0.094.33 Therefore, the ICC value of 0.041 to 0.053 in our study suggests a moderate 
variation across HRRs in patient adherence relatively to typical regional variations in 
healthcare settings.
We ranked the HRRs based on the adjusted proportion of patients adherent and listed the 
HRRs below the 5th percentile. There are limitations of using quantitative comparison as 
performance indicators since it remains difficult to determine the meaningful extent of 
differences in the comparison to differentiate individual clusters in their performance.29,34,35 
However, HRRs with the adjusted proportion of patients adherent below the 5th percentile 
may be reasonably considered as outliers.
The considerable increased hospital readmission and mortality risk associated with non-
adherence to the evidence-based preventive therapies has received increasing attention from 
clinicians, researchers and policy makers.10,12,36–40 Given the prevalent non-adherence to 
evidence-based preventive therapies among patients, a public health approach to address 
non-adherence may be an important. In this study, the observed moderate variation in patient 
adherence across relatively small health service regions was unexplained by non-modifiable 
factors such as patient sociodemographic and clinical characteristics. This unexplained 
small-area variation in patient adherence may suggest that modifiable factors such as 
provision and quality of care may play an important role. Studies have suggested that the 
geographic variation in prescribing of evidence-based therapies may stem from the 
disparities in the provision of quality of care and processes across regions.13–18,41,42 A 
complexity in the processes of care potentially impacting patient long-term adherence is the 
involvement of patients, multiple care providers including cardiologists, family care 
providers, and pharmacists across institution and community settings. It has also been shown 
that care processes and provisions such as continuity of care (e.g., follow-up care and 
medication reconciliation), coordination of care (e.g., “therapeutic complexity” – having 
multiple prescribers, pharmacies, and care providers), and provider-patient communication 
affected patient adherence to prescribed preventive therapies.43–45 It is possible that 
differences in the quality of care process and provision and health literacy level across 
HRRs may be important contributors to the variation in patient adherence to evidence-based 
therapies unexplained by patient sociodemographic and clinical characteristics. Future 
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studies are necessary to identify the differences in care process and provision that may lead 
to the small-area variation in patient adherence.
National policies and programs, for example the Health Plan Employer Data and 
Information Set (HEDIS) Measures and the GWTG program, are in place to enhance the 
prescribing of evidence-based therapies for AMI care, and improvements have been 
achieved in prescribing β-blockers, statins and ACEIs/ARBs at discharge.3–5 However, there 
is a need for more national programs and policies that specifically aim to improve the care 
process associated with patient adherence to the evidence-based preventive therapies. Our 
study suggests that it may be useful for programs to add emphasis on small health service 
areas with high prevalence of non-adherence. Reasons for patient non-adherence are usually 
multifactorial.12,38,40,46 The proportion of patients adherent across HRRs added a 
statistically significant but mild prediction of individual patient adherence beyond non-
modifiable individual patient characteristics. The mildly added prediction for individual 
patients suggests that program with emphasis on small health services areas with high 
prevalence of non-adherence needs to be coupled with interventions on various individual 
risk factors to improve adherence.
Limitations of this study are common to all studies using healthcare administrative claims. 
To address those limitations, we applied previously validated algorithms in the literature to 
measure index AMI with a positive predictive value of 89% to 97%.19–21 Our data cannot 
elucidate whether non-adherence was due to adverse side effects. However, the 3 evidence-
based therapies are generally well-tolerated, and the incidence of adverse side effects is low; 
it is also unlikely that adverse effects would be differential across geographic regions.7 We 
have also adjusted for potential intolerant and contraindicative conditions to the use of the 
therapies at baseline. We used prescription refill records to measure adherence without 
information on actual medication taking. However, prescription refill records have been 
shown to have good validity and correlation with pill counts.7,23 The nature of retrospective 
cohort analysis using claims files does not allow us to measure all potential confounding 
factors. It remains possible that unmeasured confounders may contribute to the observed 
variation in the prevalence of non-adherence across HRRs. However, it is suggested that 
important bias in regional variation in medical practice will be rare, and regional variation in 
medical practice as proxy for confounder misclassification will typically be negligible.47 
Patients discharged to home may have difference adherence from that of patients discharged 
to skilled nursing facilities. Future study may be needed to assess whether small-area 
variation in patient adherence may differ by discharge location. Our study has several 
strengths. To our knowledge, the small-area variation in patient adherence in preventive 
therapies has not been assessed in other studies. We utilized a nationally representative 
cohort of 100% Medicare patient samples who were enrolled in the fee-for-service and Part 
D program and the use of recent 2007–2009 data representing contemporary settings.
In summary, moderate variation across small geographic area in patient adherence to 
evidence-based preventive therapies exists among older adults post AMI. This moderate 
small-area variation in patient adherence was unexplained by non-modifiable patient 
sociodemographic and clinical characteristics.
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Maps of variations in the adjusted proportion of AMI patients adherent to evidence-based 
preventive therapies in the 12 months after AMI discharge across hospital referral regions 
(HRRs)
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Scatter plots of the adjusted proportion of AMI patients adherent to evidence-based 
preventive therapies across HRRs by the adjusted proportion and sample size
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Table 2
The intracluster (intraclass) correlation coefficients (ICC) for measuring the extent of variation in patient 
adherence to post AMI therapies across hospital referral regions
Therapy mean 95% Confidence Intervals (CI)†
β-blockers 0.053 (0.043, 0.064)
ACEIs/ARBs 0.050 (0.039, 0.061)
Statins 0.041 (0.031, 0.052)
Abbreviation: ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotension receptor blockers.
†
The 95% CI was generated by a bootstrap of 1000 iterations with replacement from all patients with respective preventive therapy in the study 
cohort.




































































































































































































































































































































































































Med Care. Author manuscript; available in PMC 2015 March 15.
